{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:05:07Z","timestamp":1784005507982,"version":"3.55.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Papulopustular eruption is a characteristic dermatologic toxicity of classical epidermal growth factor receptor (EGFR) inhibitors and may impair quality of life, supportive-care needs, and treatment continuity. Although frequently termed acneiform, it is distinct from acne vulgaris and is better understood as a therapy-associated folliculocentric inflammatory eruption. Related papulopustular phenotypes have been reported with MEK inhibitors and newer EGFR-targeting regimens such as amivantamab, but these settings differ in pharmacology, evidence base, and clinical behavior. This Mini Review summarizes these eruptions across three evidence contexts: classical EGFR inhibitor-associated eruption, MEK inhibitor-associated overlapping eruption, and amivantamab-associated scalp-predominant disease in an EGFR\/MET bispecific-antibody setting. We discuss mechanisms using an evidence-tiered approach, distinguishing relatively direct evidence for KLF4\/IL-36\u03b3 signaling and\n                    <jats:italic>Cutibacterium acnes<\/jats:italic>\n                    -amplified neutrophilic inflammation from emerging or hypothesis-generating links involving hair-follicle immune dysregulation, JAK-associated signaling, and destructive scalp phenotypes. Finally, we outline evidence-aware management considerations, separating guideline-supported conventional care from lower-level evidence for refractory, superinfected, or scalp-destructive presentations.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1864260","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:21:57Z","timestamp":1784002917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of Jiangsu University, Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of Jiangsu University, Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2022.10.004","article-title":"EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects","volume":"98","author":"Recuero","year":"2023","journal-title":"Bras Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000371821","article-title":"Acneiform rash induced by EGFR inhibitors: review of the literature and new insights","volume":"1","author":"Fabbrocini","year":"2015","journal-title":"Skin Appendage Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15704","article-title":"Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review","volume":"22","author":"Yuan","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00790-8","article-title":"Diagnosis and management of dermatologic adverse events from systemic melanoma therapies","volume":"24","author":"Fay","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886)","volume":"29","author":"Balagula","year":"2011","journal-title":"Invest New Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.11.027","article-title":"Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: a case series","volume":"47","author":"George","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2026.108950","article-title":"Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm","volume":"213","author":"Nikolaou","year":"2026","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70347","article-title":"Cutaneous toxicities associated with amivantamab in patients with non-small cell lung cancer: a systematic review","author":"Koumprentziotis","year":"2026","journal-title":"Int J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.04.018","article-title":"EGFR controls hair shaft differentiation in a p53-independent manner","volume":"15","author":"Amberg","year":"2019","journal-title":"iScience"},{"key":"B13","doi-asserted-by":"publisher","first-page":"199ra111","DOI":"10.1126\/scitranslmed.3005886","article-title":"Epidermal EGFR controls cutaneous host defense and prevents inflammation","volume":"5","author":"Lichtenberger","year":"2013","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128678","article-title":"IL-36\u03b3 drives skin toxicity induced by EGFR\/MEK inhibition and commensal Cutibacterium acnes","volume":"130","author":"Satoh","year":"2020","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/bjd\/ljae243","article-title":"Epidermal growth factor receptor\/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege","volume":"191","author":"Rutkowski","year":"2024","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae284","article-title":"Impact of epidermal growth factor receptor and mitogen-activated kinase inhibition on hair follicles (HFs): partial HF immune privilege collapse and excessive interleukin-33 secretion","volume":"191","author":"Fukuda","year":"2024","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00166-3","article-title":"JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia","volume":"16","author":"Strobl","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq7074","article-title":"Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans","volume":"16","author":"You","year":"2024","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20391","article-title":"Management of human epidermal growth factor receptor inhibitors-related acneiform rash: a position paper based on the first Europe\/USA Delphi consensus process","volume":"39","author":"Apalla","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.117","article-title":"Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial","volume":"20","author":"Cho","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04791.x","article-title":"Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors","volume":"50","author":"Balagula","year":"2011","journal-title":"Int J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2781-y","article-title":"Xerosis and pruritus as major EGFRI-associated adverse events","volume":"24","author":"Clabbers","year":"2016","journal-title":"Support Care Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3231-1","article-title":"EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections","volume":"24","author":"Braden","year":"2016","journal-title":"Support Care Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0744-x","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07257-2","article-title":"Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients","volume":"30","author":"Ibraheim","year":"2022","journal-title":"Support Care Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70360","article-title":"Dermatologic adverse events associated with amivantamab: a multicentre study","author":"Nikolaou","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001494","article-title":"EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines","volume":"34","author":"Nowaczyk","year":"2023","journal-title":"Anticancer Drugs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1303a180","article-title":"Folliculitis-decalvans like alopecia during treatment with EGFR inhibitors for lung cancer: a case series of 6 patients","volume":"13","author":"Starace","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.14.2.319","article-title":"Involvement of hepatocyte growth factor\/scatter factor and Met receptor signaling in hair follicle morphogenesis and cycling","volume":"14","author":"Lindner","year":"2000","journal-title":"FASEB J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0051","article-title":"Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors","volume":"21","author":"Hofheinz","year":"2016","journal-title":"Oncologist"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.09.004","article-title":"Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review","volume":"38","author":"Baas","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"104583","DOI":"10.1016\/j.ad.2025.104583","article-title":"Role of oral tetracyclines in preventing acneiform rash in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review","volume":"117","author":"de Sousa","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0988-5","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP","volume":"11","author":"Kobayashi","year":"2015","journal-title":"Future Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy015","article-title":"EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity","volume":"29","author":"Hofheinz","year":"2018","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy451","article-title":"Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial","volume":"29","author":"Gaiser","year":"2018","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06874-1","article-title":"Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part)","volume":"30","author":"Kikuchi","year":"2022","journal-title":"Support Care Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.70087","article-title":"Management of treatment resistant EGFR inhibitor-induced papulopustular exanthema with isotretinoin and dapsone","author":"Dixit","year":"2026","journal-title":"Australas J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2025.1731646","article-title":"Patient perspectives on epidermal growth factor receptor inhibitor-induced skin toxicities: a qualitative study","volume":"16","author":"Li","year":"2026","journal-title":"Front Psychol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/jjns.12321","article-title":"Relationships between quality of life and skin toxicities of epidermal growth factor receptor inhibitors in cancer patients: a literature review","volume":"17","author":"Hirayama","year":"2020","journal-title":"Jpn J Nurs Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clcc.2020.01.001","article-title":"Management of EGFR inhibitor-induced skin toxicity and factors impacting patients\u2019 adherence to skin toxicity treatment: health care provider and patient surveys in European oncology centers","volume":"19","author":"Kafatos","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo0684","article-title":"Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions","volume":"15","author":"Friedman","year":"2023","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:21:58Z","timestamp":1784002918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1864260"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1864260","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1864260"}}